7:00 a.m. - 5:30 p.m. |
Registration |
7:00 a.m. - 8:00 a.m. |
Continental Breakfast |
7:55 a.m. - 8:00 a.m. |
Day Two Welcome
Cherie-Ann O. Nathan, MD, Louisiana State University Health Sciences Center, Shreveport, Louisiana [S] |
8:00 a.m. - 9:30 a.m. |
Larynx/Hypopharynx
Moderator: Robert I. Haddad, MD, Dana-Farber Cancer Institute, Boston [M]
- Guidelines for Larynx/Hypopharynx - Sharon Spencer, MD, University of Alabama at Birmingham, Birmingham, Alabama [M]
- Surgical Approaches for Early Laryngeal Cancer - Brandon Jackson Baird, MD, University of Chicago, Chicago [S]
- Role of Induction - Francis P. Worden, MD, University of Michigan Health System, Ann Arbor, Michigan [M]
- Guidelines for Target Delineation - Matthew Witek, MD, MS, University of Maryland School of Medicine, Baltimore [R]
- Questions and Answers
|
9:30 a.m. - 10:15 a.m. |
Keynote II: Immune-related Therapies and Clinical Trial Updates
Moderator: Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California [R]
Panelist: Ezra Cohen, MD, University of California San Diego, La Jolla, California [M]
30 minutes |
10:15 a.m. - 10:45 a.m. |
Coffee Break |
10:45 a.m. - 12:15 p.m. |
Oral Abstract Session
Moderator: Robert I. Haddad, MD, Dana-Farber Cancer Institute, Boston [M]
- 10: Long-Term Update of a Phase II Study of Concurrent Chemoradiotherapy Using Radiation + Bevacizumab (BV) For Locally or Regionally Advanced Nasopharyngeal Cancer (NPC): RTOG 0615 - Nancy Y. Lee, MD, FASTRO, Memorial Sloan Kettering Cancer Center, New York
- 11: A Combination of Three Biomarkers for HNSCC Prognostication Following Chemoradiotherapy - James Rocco, MD, PhD, The Ohio State University, Columbus, Ohio
- 12: Primary Chemoradiotherapy or Transoral Robotic Surgery for Stage I-II HPV-associated Oropharyngeal Squamous Cell Carcinoma - Ryan Hughes, MD, Wake Forest School of Medicine, Winston Salem, North Carolina
- 13: Imaging Response Versus Operative Laryngoscopy Assessment of Induction Chemotherapy Response in an Induction Bioselection Approach to Larynx Cancer - Laila Gharzai, MD, University of Michigan, Ann Arbor, Michigan
- 14: Circulating Tumor Associated Cells in Head and Neck Cancers are Resistance Educated per Previous Chemotherapy Treatments - Timothy Crook, BSc, PhD, MBBS, FRCP, Royal Surrey County Hospital, Guildford, England
- 15: An Open-label, Non-randomized, Multi-arm, Phase II Trial Evaluating Pembrolizumab Combined with Cetuximab in Patients (pts) with Recurrent/metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Updated Results of Cohort 1 Analysis - Assuntina G. Sacco, MD, University of California San Diego, La Jolla, California
- 16: Delivering High-quality Head and Neck Low-risk Clinical Target Volumes through a Fully-automated Artificial Intelligence-based Approach - Carlos Cardenas, PhD, MD Anderson Cancer Center, Houston
- LBA 1: Progression-free survival, overall survival and immunophenotyping outcomes for patients with stage III-IV head and neck cancer and cisplatin contraindication treated with definitive radiotherapy plus pembrolizumab - Jared Weiss, MD, University of North Carolina, Chapel Hill, North Carolina
- LBA 2: Tumor Outcomes of Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer - Carryn Anderson, MD, University of Iowa Hospitals and Clinics, Iowa City, Iowa
|
12:15 p.m. - 1:15 p.m. |
Lunch in the Exhibit Hall
Trainee and Early-career Networking Luncheon
This is an invaluable opportunity for any attendee who is less than three years out of training to speak with and learn from experts in the head and neck cancer care community. Join faculty in an informal setting to discuss topics such as how to build a network outside of your institution, how to establish yourself as a clinical investigator, how to evaluate job opportunities and how to move on after your first job. By attending, you will gain meaningful insight into career paths and development that will help support you in your medical career. Those interested in attending must register for this free, ticketed event.
Speakers:
- Quynh-Thu Le, MD, FASTRO, Stanford University, Stanford, California [R]
- Maie St. John, MD, PhD, UCLA Medical Center, Los Angeles [S]
- Francis P. Worden, MD, University of Michigan Health System, Ann Arbor, Michigan [M]
|
1:15 p.m. - 2:45 p.m. |
Rare Cancers of the Head and Neck
Moderator: Jonathan J. Beitler, MD, MBA, FACR, FASTRO, Emory University School of Medicine, Atlanta [R]
- Challenges in Salivary Gland and Sinonasal Neuroendocrine Pathology - Annemieke van Zante, MD, PhD, University of California, San Francisco [Pathologist]
- Salivary Gland Cancer - Alan L. Ho, MD, PhD, Memorial Sloan Kettering Cancer Center, New York [M]
- Esthesioneuroblastoma - Jonathan J. Beitler, MD, MBA, FACR, FASTRO, Emory University School of Medicine, Atlanta [R]
- Sinonasal Neuroendocrine and Undifferentiated Carcinomas - Ehab Y. Hanna, MD, FACS, MD Anderson Cancer Center, Houston [S]
|
2:45 p.m. - 3:15 p.m. |
Coffee Break |
3:15 p.m. - 4:30 p.m. |
Breakout Session I: Advances in Molecular Imaging
Moderator: Eben L. Rosenthal, MD, Stanford University, Stanford, California [S/Radiologist]
- Intraoperative Molecular Imaging - Eben L. Rosenthal, MD, Stanford University, Stanford, California [S/Radiologist]
- FDG PET/CT and Head and Neck Cancer - Jian Q. (Michael) Yu, MD, FACNM, FRCPC, Fox Chase Cancer Center, Philadelphia [Radiologist]
- Potential Theranostic Agents in Head and Neck Cancer - Ana P. Kiess, MD, PhD, Johns Hopkins University, Baltimore [R]
- Questions and Answers
Breakout Session II: Survivorship
Moderator: Stuart J. Wong, MD, Medical College of Wisconsin, Milwaukee, Wisconsin [M]
- Financial Toxicity and Employment in Head and Neck Cancer Patients - Barbara A. Murphy, MD, Vanderbilt University Medical Center, Nashville, Tennessee [M]
- Vascular Disease in Head and Neck Cancer Survivorship - David M. Brizel, MD, Duke Cancer Center, Durham, North Carolina [R]
- Are Current PROs Adequate for Head and Neck Cancer Patients? - Jolie Ringash, MD, FRCPC, MSc, University of Toronto, Toronto [R]
- Optical Imaging Technologies for Characterization of Oral Neoplasia - Ann Gillenwater, MD, MD Anderson Cancer Center, Houston [S]
- Questions and Answers
|
4:30 p.m. - 5:30 p.m. |
Tumor Board: Advanced Disease
Moderator: David Eisele, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore [S]
Panelists:
- Carol R. Bradford, MD, MS, University of Michigan, Ann Arbor, Michigan [S]
- Lara Dunn, MD, Memorial Sloan Kettering Cancer Center, New York [M]
- Tabby Kennedy, MD, University of Wisconsin, Madison, Wisconsin [Radiologist]
- Susan Müller, DMD, Emory University, Atlanta [Pathologist]
- Brian O'Sullivan, MD, FASTRO, Princess Margaret Hospital, Toronto [R]
|